Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Andreano, 2020, SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma, bioRxiv Aricescu, 2006, A time- and cost-efficient system for high-level protein production in mammalian cells, Acta Crystallogr D Biol Crystallogr, 62, 1243, 10.1107/S0907444906029799 Baden, 2021, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N. Engl. J. Med., 384, 403, 10.1056/NEJMoa2035389 Baum, 2020, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science, 369, 1014, 10.1126/science.abd0831 Caly, 2020, Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia, Med. J. Aust., 212, 459, 10.5694/mja2.50569 Cerutti, 2021, Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite Lead Contact, bioRxiv Chi, 2020, A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2, Science, 369, 650, 10.1126/science.abc6952 Dejnirattisai, 2021, The antigenic anatomy of SARS-CoV-2 receptor binding domain, Cell, 184, 10.1016/j.cell.2021.02.032 Faria, 2021, Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology - Virological, virological.org Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Huang, 2020, Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71, Nat. Commun., 11, 5253, 10.1038/s41467-020-19013-3 Kemp, 2021, SARS-CoV-2 evolution during treatment of chronic infection, Nature, 10.1038/s41586-021-03291-y Keogh-Brown, 2020, The impact of Covid-19, associated behaviours and policies on the UK economy: A computable general equilibrium model, SSM Popul. Health, 12, 100651, 10.1016/j.ssmph.2020.100651 Krammer, 2020, SARS-CoV-2 vaccines in development, Nature, 586, 516, 10.1038/s41586-020-2798-3 Ku, 2021, Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape, Nat. Commun., 12, 469, 10.1038/s41467-020-20789-7 Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 Madhi, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) cOVID-19 vaccine against the B.1.351 variant in South Africa, medRxiv McCallum, 2021, N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2, bioRxiv Nettleship, 2008, A pipeline for the production of antibody fragments for structural studies using transient expression in HEK 293T cells, Protein Expr Purif, 62, 83, 10.1016/j.pep.2008.06.017 Polack, 2020, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med., 383, 2603, 10.1056/NEJMoa2034577 Seemann, 2020, Tracking the COVID-19 pandemic in Australia using genomics, Nat. Commun., 11, 4376, 10.1038/s41467-020-18314-x Shang, 2020, Structural basis of receptor recognition by SARS-CoV-2, Nature, 581, 221, 10.1038/s41586-020-2179-y Shi, 2020, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, Nature, 584, 120, 10.1038/s41586-020-2381-y Starr, 2020, Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding, Cell, 182, 1295, 10.1016/j.cell.2020.08.012 Supasa, 2021, Reduced neutralization of SARS-CoV-2 B.1.1.7 variant from naturally acquired and vaccine induced antibody immunity, SSRN, 10.2139/ssrn.3775873 Tatusov, 2000, The COG database: a tool for genome-scale analysis of protein functions and evolution, Nucleic Acids Res., 28, 33, 10.1093/nar/28.1.33 Tegally, 2021, Sixteen novel lineages of SARS-CoV-2 in South Africa, Nat. Med., 10.1038/s41591-021-01255-3 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Voysey, 2021, Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1nCoV-19 (AZD1222) vaccine, SSRN, 10.2139/ssrn.3777268 Wajnberg, 2020, Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Science, 370, 1227, 10.1126/science.abd7728 Yang, 2020, COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19, Antib. Ther., 3, 205 Yuan, 2020, Structural basis of a shared antibody response to SARS-CoV-2, Science, 369, 1119, 10.1126/science.abd2321 Zahradník, 2021, SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor, bioRxiv Zhou, 2020, Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient, Nat Struct Mol Biol, 27, 950, 10.1038/s41594-020-0480-y